Skip to content
Clinical Trials – home

Studienzentrum Dr. Beate Schwarz

Verified siteinfoFast reply

Germany Bismarkstraße 49, 89129 Langenau, Germany

  • 4 trials recruiting
  • Hidradenitis · Psoriasis · Chronic spontaneous urticaria
  • Adults and children

About Specializations

Studienzentrum Dr. Beate Schwarz in Langenau, Germany specialises in clinical trials of conditions such as Hidradenitis, Psoriasis, Chronic spontaneous urticaria, Psoriatic arthropathy, and other specialisations. This site conducts important research.

Main research areas of the site

Skin and Connective Tissue Diseases

At Studienzentrum Dr. Beate Schwarz in Langenau, much of the research focuses on dermatology, especially psoriasis, atopic dermatitis, acne, rosacea, and skin ulcers. These studies are designed to test new treatments, compare them with current options, and better understand how to improve symptom control and skin healing.

  • Moderate-to-severe plaque psoriasis and related inflammatory skin disease
  • Atopic dermatitis, nummular dermatitis, and other eczema conditions
  • Hidradenitis suppurativa and chronic venous ulcers
  • Acne, rosacea, actinic keratosis, and candidiasis of the skin

The site is actively involved in evaluating therapies that may reduce inflammation, relieve itch, support wound closure, and improve day-to-day quality of life for people with chronic skin diseases.

Immune System Diseases

Another major area of research at this health care site is immune-mediated disease, with trials centered on conditions such as chronic spontaneous urticaria, psoriatic arthritis, and severe forms of atopic dermatitis. The goal is to assess whether new therapies can more effectively control immune-driven symptoms and improve patient outcomes.

  • Chronic spontaneous urticaria and itch-related disease
  • Active psoriatic arthritis
  • Moderate-to-severe atopic dermatitis
  • Immune-related inflammation linked to chronic skin disorders

These trials commonly compare emerging treatments with placebo or existing care to better define treatment effectiveness and safety in immune system diseases.

Nervous System Diseases

The research portfolio also includes studies in nervous system diseases, particularly conditions where nerve-related symptoms such as persistent itch play an important role. This includes work on notalgia paresthetica, where investigators are exploring whether new therapies can reduce discomfort and improve symptom control.

  • Moderate-to-severe pruritus associated with notalgia paresthetica
  • Persistent itch and sensory symptoms affecting daily comfort
  • Symptom relief in chronic neurocutaneous conditions

These studies aim to improve understanding of difficult-to-treat itch and to identify better ways to manage long-lasting nerve-related skin symptoms.

Parasitic Diseases

Research at the site also covers parasitic diseases, including scabies, a contagious skin condition that causes intense itching and irritation. The trials in this area focus on evaluating treatment effectiveness and confirming that new or existing therapies can clear infection-related skin symptoms.

  • Scabies treatment and symptom resolution
  • Clinical response after topical therapy
  • Improving control of itch and skin irritation caused by infestation

These studies are intended to support better treatment choices for patients affected by parasitic skin infections.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Bismarkstraße 4989129 LangenauGermany
Recruiting now
4 trials
Conditions studied
9
Partner status
Verified site

More sites in LangenauGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

17 clinical trials

Eczema nummular

Recruiting

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Previously Used Biologic Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-77242113
  • Sponsor:Janssen Cilag International

Study on the Effectiveness of Green Tea Leaf Extract Ointment for Adults with Actinic Keratosis on the Scalp and Face

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camellia Sinensis (Green Tea) Leaf Extract
  • Sponsor:Aresus Pharma GmbH

Psoriasis

Not yet recruiting

Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen Cilag International

Hidradenitis

Not recruiting

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:JNJ-77242113
  • Sponsor:Janssen Cilag International

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of JNJ-95475939 and Dupilumab for Treating Moderate to Severe Atopic Dermatitis in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Janssen Cilag International

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-77242113
  • Sponsor:Janssen Cilag International

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Psoriasis

Not recruiting

Study on the Effects of JNJ-81241459 for Patients with Moderate to Severe Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-81241459
  • Sponsor:Janssen Cilag International

Hidradenitis

Not recruiting

Study on the Effects of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.